Uruguay’s Cannabis Industry Struggles Amid Export Barriers, Price Drops

Uruguay, the first country in the world to legalize adult-use marijuana in 2013, initially made headlines as a pioneer in cannabis regulation. However, despite early momentum, the industry now faces significant hurdles in export growth, driven by low prices, international trade restrictions and regulatory obstacles. Today, the sector comprises nearly 100 projects and employs around 756 people, with 77% of the workforce based outside the capital.

Challenges Impacting Uruguay’s Cannabis

According to a recent article in Ámbito Financiero, half of the companies authorized for cultivation and industrialization in 2023 succeeded in exporting flowers and medical products. Yet, revenues fell sharply, with a 44% decline from the previous year, totaling just $3 million from 25 tons of hemp sub-products. The dip is largely attributed to low international prices, undermining the financial stability of many enterprises.

The industry remains dominated by small and medium-sized enterprises (SMEs), which account for 96% of the 90 active projects, while only 4% are considered large-scale companies. Despite these challenges, Uruguay managed to rank as the eighth-largest exporter of medical cannabis in 2022, capturing a 2.1% share of the global market with exports of about 15 tons. Nonetheless, production volumes saw a 14% drop compared to the previous year.

Regulatory Gaps Hinder Export Growth Amid Business Exits

As a country with 3.4 million inhabitants, exports play a key role in the growth of the industry. However, one of the major barriers to growth is the restrictive international trade environment. Regulations under the United Nations, combined with diverse national laws, have limited market access and constrained the industry’s expansion. The Ámbito Financiero article notes that the absence of a comprehensive regulatory framework has further hampered efforts to increase exports, stifling the potential of Uruguay’s cannabis in the global marketplace.

Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you’re serious about the business, you can’t afford to miss out.

Moreover, this challenging landscape has led some companies to exit the market. Aurora Cannabis ACB, for instance, announced its departure from Uruguay in September, citing unmet growth criteria. Similarly, the collapse of Pharmin—whose $9.5 million facility sold for a mere $335,000 at auction—highlights the ongoing uncertainty plaguing the sector.

Seeking New Investors For Uruguay’s $30M Legal Market

Despite these setbacks, the industry is actively seeking new investors to reinvigorate growth. Uruguay’s legal cannabis sector still delivers notable benefits, generating approximately $30 million annually—funds that once fueled criminal organizations. The introduction of new strains like Épsilon, featuring a 15% THC content, has been met with strong consumer demand.

Read Also: ‘Diamond In The Rough’ Of Latin American Cannabis: Puerto Rico’s Success Secret Explained

Meanwhile, some Latin American nations are reassessing their cannabis policies, hinting at possible shifts. In July 2023, Brazil legalized the possession of marijuana, though sales are still illegal. Argentina’s state-owned company Cannava secured multi-million-dollar contracts to export medical marijuana flowers to Germany, Australia and Portugal.

As countries in the region debate drug policy reforms, global changes could be crucial for unlocking the industry’s potential. Until then, Uruguay’s cannabis industry must navigate difficult waters to sustain its growth.

Read Next:

Image created with AI tools.